Ginsenoside Rg3
20(S)-Ginsenoside Rg3, triterpenoid saponin from Panax ginseng
Written by Aaron CuhaReviewed Sep 2026
Also known as: 20(S)-Rg3, Rg3, Ginsenoside Rg3
A ginseng saponin whose effect on senescence runs in both directions depending on the cell: it reversed replicative senescence in human fibroblasts in culture and is studied as a senescence inducer in tumour cells. The only human data are pharmacokinetic.
Overview
Ginsenoside Rg3 is a triterpenoid saponin from Panax ginseng, studied mainly in China and Korea. Its senescence literature is cell culture. The 20(S) stereoisomer reversed replicative senescence in human dermal fibroblasts by restoring ATP levels and the NAD+ to NADH ratio and by modulating Akt, mTOR and sirtuin signalling, while the 20(R) stereoisomer did not alter those pathways. In human and rat astrocytes, Rg3 prevented hydrogen peroxide-induced senescence and suppressed the senescence-associated secretory factors interleukin 6 and interleukin 8, but it did not reverse senescence once established.
The direction of effect is context dependent, and this matters. In fibroblasts Rg3 is described as reversing senescence, which is the opposite of a senolytic action; senolytics kill senescent cells rather than restoring them. In tumour cell work Rg3 is studied as an agent that induces senescence. No study has resolved which of these applies in a living person, because the question has not been asked in one.
Human data exist, and they are pharmacokinetic only. A first-in-human study gave single intramuscular doses of 10 to 60 mg to 24 healthy Chinese volunteers and 30 mg daily for 15 days to 9 more. Time to peak concentration was 4 hours, elimination half-life ranged from about 32 to 54 hours across doses, and the compound was generally well tolerated. An earlier Chinese-language study characterised the 20(R) isomer in volunteers. Neither measured senescence. No senolytic has improved a clinical outcome in a randomised trial in humans, and Rg3 has not been tested against a senescence endpoint in a person.
Mechanism of action
In cultured human fibroblasts, 20(S)-Rg3 restored ATP and the NAD+ to NADH ratio, downregulated PI3K and Akt through mTOR inhibition with p53 and p21 involvement, and activated sirtuin 3 and PGC1alpha to stimulate mitochondrial biogenesis; the 20(R) stereoisomer did not. In astrocyte culture, Rg3 suppressed interleukin 6 and interleukin 8 via NF-kappaB and p38 MAPK, a senomorphic action. In human pharmacology, only absorption and elimination have been characterised.
Human evidence
Human data exist but are pharmacokinetic only: how the compound is absorbed and cleared after intramuscular dosing in healthy volunteers. No human study has measured any senescence, ageing or clinical endpoint.
- 24 healthy Chinese adults, single ascending intramuscular doses of 10 to 60 mg: peak concentration at 4 hours, elimination half-life 32.0 to 53.9 hours, generally well tolerated.
- 9 healthy adults, 30 mg daily intramuscular for 15 days: accumulation ratio 1.7 at steady state.
- A 2001 Chinese-language study characterised the 20(R) isomer in volunteers.
- No registered trial of Rg3 for senescence, frailty or any ageing endpoint was located.
What this does not tell you: Pharmacokinetics tell you the compound reaches the blood and how long it stays. They do not tell you it does anything. The published human dosing is intramuscular, while supplement users take it by mouth, and oral ginsenoside absorption depends heavily on gut microbial conversion, which these studies did not address.
Reading the research record
Rg3 does not fit the senolytic template and should not be filed under it without qualification. A senolytic kills senescent cells. The fibroblast work describes the opposite action, reversal of the senescent state, and the astrocyte work describes a senomorphic action, suppression of the secretory phenotype without killing anything. Elsewhere in the literature Rg3 is investigated for inducing senescence in tumour cells. Three different directions, all in cell culture.
Ginsenosides are unpatentable plant constituents sold as supplements, which is the usual reason a compound accumulates mechanistic papers and no outcome trials. The absence of trials means neither benefit nor harm from long-term use has been looked for systematically.
The evidence, charted
Fig. 1 · evidence composition
2of 5 citations (40%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 5 distinct years, 2001 to 2020, counted from the citation list on this page. The newest citation on file is from 2020, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Human2016
Pharmacokinetics of Single Ascending Doses and Multiple Doses of 20(S)-Ginsenoside Rg3 in Chinese Healthy Volunteers
First-in-human pharmacokinetics. 24 healthy adults received single intramuscular doses of 10, 30 or 60 mg; 9 received 30 mg daily for 15 days. Time to peak 4 hours, elimination half-life 32.0 to 53.9 hours depending on dose, accumulation ratio 1.7 at steady state, urinary excretion under 1 percent. Generally well tolerated. No senescence or efficacy endpoint.
European Journal of Drug Metabolism and Pharmacokinetics - Human2001
Pharmacokinetic studies of 20(R)-ginsenoside Rg3 in human volunteers
Chinese-language pharmacokinetic study of the 20(R) stereoisomer in volunteers. Human dosing data only; no clinical endpoint.
Acta Pharmaceutica Sinica - In vitro2020
Stereoisomer-specific ginsenoside 20(S)-Rg3 reverses replicative senescence of human diploid fibroblasts via Akt-mTOR-Sirtuin signaling
Cultured human dermal fibroblasts. 20(S)-Rg3 reversed replicative senescence by restoring ATP and the NAD+ to NADH ratio and modulating Akt, mTOR and sirtuin signalling; the 20(R) isomer did not. Reversal of senescence, not clearance of senescent cells.
Journal of Ginseng Research - In vitro2017
Ginsenoside Rg3 Prevents Oxidative Stress-Induced Astrocytic Senescence and Ameliorates Senescence Paracrine Effects on Glioblastoma
Human astrocytic cells and primary rat astrocytes. Rg3 at 5 micrograms per millilitre prevented hydrogen peroxide-induced senescence but did not reverse it once established; at 10 micrograms per millilitre it suppressed interleukin 6 and interleukin 8 through NF-kappaB and p38 MAPK.
Molecules - Review2019
Emerging senolytic agents derived from natural products
Review of plant-derived senotherapeutics. Useful for placing ginsenosides among compounds whose senescence effects are characterised in cells rather than in people.
Mechanisms of Ageing and Development
Frequently asked questions
Is ginsenoside Rg3 a senolytic?
Not as the term is normally used. In cultured human fibroblasts it reversed replicative senescence rather than killing senescent cells, and in astrocytes it suppressed inflammatory secretion without clearing the cells. In tumour cell studies it has been investigated as a senescence inducer. None of this has been tested in a person.
What is known about Rg3 in humans?
Only pharmacokinetics. In 24 healthy volunteers given single intramuscular doses of 10 to 60 mg, the peak came at 4 hours and the elimination half-life ran from about 32 to 54 hours. No human study has measured senescence or any clinical outcome.
Does the 20(S) or 20(R) form matter?
In the fibroblast work it did. The 20(S) stereoisomer reversed replicative senescence through Akt, mTOR and sirtuin signalling, and the 20(R) stereoisomer did not alter those pathways. Supplement labels frequently do not state which isomer is present.